Dr Peter Ellmark | Principal Scientist, Immuno-oncology
Alligator Bioscience Ab

Dr Peter Ellmark, Principal Scientist, Immuno-oncology, Alligator Bioscience Ab

Dr. Ellmark joined Alligator Bioscience in 2008, and as a Principal Scientist he is the Scientific lead for Alligator´s drug development Projects. He also holds a position as Associate Professor in Immunotechnology at Lund University. Dr. Ellmark´s research interest is focused on developing mono and bispecific antibodies for tumor directed immunotherapy of cancer. Dr. Ellmark earned his PhD 2002 at the Department of Immunotechnology at Lund University working on antibody engineering and CD40 antibodies.


EAC 2017 Day 1, Tuesday 31st October 2017 @ 15:10

ATOR-1015, a bispecific immunomodulatory antibody targeting OX40 and CTLA-4

  • Generation of ATOR-1015 – engineering of a stable bispecific immunomodulating bispecific antibody
  • Functional assessment of ATOR-1015 In vitro and in vivo
  • Drugability assessment of ATOR-1015

back to speakers